About virpax pharmaceuticals inc - VRPX
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.
VRPX At a Glance
Virpax Pharmaceuticals, Inc.
1055 Westlakes Drive
Berwyn, Pennsylvania 19312
| Phone | 1-610-727-4597 | Revenue | 0.00 | |
| Industry | Miscellaneous Commercial Services | Net Income | -12,067,225.00 | |
| Sector | Commercial Services | Employees | 2 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
VRPX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.009 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
VRPX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -6,033,612.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
VRPX Liquidity
| Current Ratio | 0.629 |
| Quick Ratio | 0.629 |
| Cash Ratio | 0.613 |
VRPX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -215.795 |
| Return on Equity | -2,364.822 |
| Return on Total Capital | 1,320.612 |
| Return on Invested Capital | -2,364.822 |
VRPX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |